153 related articles for article (PubMed ID: 24367220)
1. Type 1 interferon receptor in peripheral blood mononuclear cells may predict response to intra-arterial 5-fluorouracil + interferon therapy for advanced hepatocellular carcinoma.
Tomiyama Y; Yoshioka N; Yanai Y; Kawase T; Nishina S; Hara Y; Yoshida K; Korenaga K; Korenaga M; Hino K
Hepat Med; 2011; 3():45-52. PubMed ID: 24367220
[TBL] [Abstract][Full Text] [Related]
2. Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression.
Ota H; Nagano H; Sakon M; Eguchi H; Kondo M; Yamamoto T; Nakamura M; Damdinsuren B; Wada H; Marubashi S; Miyamoto A; Dono K; Umeshita K; Nakamori S; Wakasa K; Monden M
Br J Cancer; 2005 Sep; 93(5):557-64. PubMed ID: 16106266
[TBL] [Abstract][Full Text] [Related]
3. Interferon-alpha and 5-fluorouracil combination therapy after palliative hepatic resection in patients with advanced hepatocellular carcinoma, portal venous tumor thrombus in the major trunk, and multiple nodules.
Nagano H; Miyamoto A; Wada H; Ota H; Marubashi S; Takeda Y; Dono K; Umeshita K; Sakon M; Monden M
Cancer; 2007 Dec; 110(11):2493-501. PubMed ID: 17941012
[TBL] [Abstract][Full Text] [Related]
4. Activation of Wnt/beta-catenin signalling pathway induces chemoresistance to interferon-alpha/5-fluorouracil combination therapy for hepatocellular carcinoma.
Noda T; Nagano H; Takemasa I; Yoshioka S; Murakami M; Wada H; Kobayashi S; Marubashi S; Takeda Y; Dono K; Umeshita K; Matsuura N; Matsubara K; Doki Y; Mori M; Monden M
Br J Cancer; 2009 May; 100(10):1647-58. PubMed ID: 19401692
[TBL] [Abstract][Full Text] [Related]
5. Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma.
Uka K; Aikata H; Takaki S; Miki D; Kawaoka T; Jeong SC; Takahashi S; Toyota N; Ito K; Chayama K
J Gastroenterol; 2007 Oct; 42(10):845-53. PubMed ID: 17940838
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy of intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma.
Kasai K; Ushio A; Kasai Y; Sawara K; Miyamoto Y; Oikawa K; Kuroda H; Takikawa Y; Suzuki K
Int J Clin Oncol; 2011 Jun; 16(3):221-9. PubMed ID: 21132451
[TBL] [Abstract][Full Text] [Related]
7. Intra-arterial 5-fluorouracil/interferon combination therapy for hepatocellular carcinoma with portal vein tumor thrombosis and extrahepatic metastases.
Katamura Y; Aikata H; Kimura Y; Kawaoka T; Takaki S; Waki K; Hiramatsu A; Kawakami Y; Takahashi S; Ishikawa M; Hieda M; Kakizawa H; Chayama K
J Gastroenterol Hepatol; 2010 Jun; 25(6):1117-22. PubMed ID: 20074168
[TBL] [Abstract][Full Text] [Related]
8. The up-regulation of type I interferon receptor gene plays a key role in hepatocellular carcinoma cells in the synergistic antiproliferative effect by 5-fluorouracil and interferon-alpha.
Oie S; Ono M; Yano H; Maruyama Y; Terada T; Yamada Y; Ueno T; Kojiro M; Hirano K; Kuwano M
Int J Oncol; 2006 Dec; 29(6):1469-78. PubMed ID: 17088986
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of therapy for advanced hepatocellular carcinoma: intra-arterial 5-fluorouracil and subcutaneous interferon with image-guided radiation.
Chuma M; Taguchi H; Yamamoto Y; Shimizu S; Nakanishi M; Ogawa K; Sho T; Horimoto H; Kobayashi T; Nakai M; Terashita K; Sakuhara Y; Abo D; Tsukuda Y; Tsunematsu S; Hige S; Kato M; Shirato H; Asaka M
J Gastroenterol Hepatol; 2011 Jul; 26(7):1123-32. PubMed ID: 21501224
[TBL] [Abstract][Full Text] [Related]
10. Type I interferon receptor and response to interferon therapy in chronic hepatitis C patients: a prospective study.
Fujiwara D; Hino K; Yamaguchi Y; Kubo Y; Yamashita S; Uchida K; Konishi T; Nakamura H; Korenaga M; Okuda M; Okita K
J Viral Hepat; 2004 Mar; 11(2):136-40. PubMed ID: 14996348
[TBL] [Abstract][Full Text] [Related]
11. Hepatic arterial infusion of 5-fluorouracil in combination with subcutaneous interferon-alpha for advanced hepatocellular carcinoma.
Kuroda M; Kobayashi Y; Urawa N; Yamamoto M; Mifuji R; Araki J; Tanaka H; Horiike S; Itani T; Furjita N; Konishi M; Iwasa M; Kaito M; Adachi Y
Hepatogastroenterology; 2007 Mar; 54(74):518-21. PubMed ID: 17523311
[TBL] [Abstract][Full Text] [Related]
12. Similar effects of recombinant interferon-alpha-2b and natural interferon-alpha when combined with intra-arterial 5-fluorouracil for the treatment of advanced hepatocellular carcinoma.
Uka K; Aikata H; Takaki S; Miki D; Jeong SC; Hiramatsu A; Kodama H; Shirakawa H; Kawakami Y; Takahashi S; Toyota N; Ito K; Chayama K
Liver Int; 2007 Nov; 27(9):1209-16. PubMed ID: 17919232
[TBL] [Abstract][Full Text] [Related]
13. Hepatic intra-arterial interferon alpha 2b-based immunotherapy combined with 5-fluorouracil (5-FU)-based systemic chemotherapy for patients with hepatocellular carcinoma (HCC) not responsive and/or not eligible for conventional treatments: a pilot study.
Vitale FV; Romeo P; Vasta F; Panebianco V; Calì S; Rotondo S; Ferraù F; La Greca M
Anticancer Res; 2007; 27(6B):4077-81. PubMed ID: 18225574
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion.
Obi S; Yoshida H; Toune R; Unuma T; Kanda M; Sato S; Tateishi R; Teratani T; Shiina S; Omata M
Cancer; 2006 May; 106(9):1990-7. PubMed ID: 16565970
[TBL] [Abstract][Full Text] [Related]
15. Hepatic arterial infusion chemotherapy using 5-fluorouracil and systemic interferon-α for advanced hepatocellular carcinoma in combination with or without three-dimensional conformal radiotherapy to venous tumor thrombosis in hepatic vein or inferior vena cava.
Murakami E; Aikata H; Miyaki D; Nagaoki Y; Katamura Y; Kawaoka T; Takaki S; Hiramatsu A; Waki K; Takahashi S; Kimura T; Kenjo M; Nagata Y; Ishikawa M; Kakizawa H; Awai K; Chayama K
Hepatol Res; 2012 May; 42(5):442-53. PubMed ID: 22176468
[TBL] [Abstract][Full Text] [Related]
16. Debulking surgery followed by intraarterial 5-fluorouracil chemotherapy plus subcutaneous interferon alfa for massive hepatocellular carcinoma with multiple intrahepatic metastases: a pilot study.
Tanaka K; Yabushita Y; Nakagawa K; Kumamoto T; Matsuo K; Taguri M; Endo I
Eur J Surg Oncol; 2013 Dec; 39(12):1364-70. PubMed ID: 24183169
[TBL] [Abstract][Full Text] [Related]
17. Randomized, phase II study comparing interferon combined with hepatic arterial infusion of fluorouracil plus cisplatin and fluorouracil alone in patients with advanced hepatocellular carcinoma.
Yamashita T; Arai K; Sunagozaka H; Ueda T; Terashima T; Yamashita T; Mizukoshi E; Sakai A; Nakamoto Y; Honda M; Kaneko S
Oncology; 2011; 81(5-6):281-90. PubMed ID: 22133996
[TBL] [Abstract][Full Text] [Related]
18. Intra-arterial 5-fluorouracil/interferon combination therapy for advanced hepatocellular carcinoma with or without three-dimensional conformal radiotherapy for portal vein tumor thrombosis.
Katamura Y; Aikata H; Takaki S; Azakami T; Kawaoka T; Waki K; Hiramatsu A; Kawakami Y; Takahashi S; Kenjo M; Toyota N; Ito K; Chayama K
J Gastroenterol; 2009; 44(5):492-502. PubMed ID: 19330281
[TBL] [Abstract][Full Text] [Related]
19. Decreased catabolism of fluorouracil in peripheral blood mononuclear cells during combination therapy with fluorouracil, leucovorin, and interferon alpha-2a.
Yee LK; Allegra CJ; Steinberg SM; Grem JL
J Natl Cancer Inst; 1992 Dec; 84(23):1820-5. PubMed ID: 1433371
[TBL] [Abstract][Full Text] [Related]
20. Expression of type I interferon receptor as a predictor of clinical response to interferon-alpha therapy of gastrointestinal cancers.
Ota H; Nagano H; Doki Y; Sekimoto M; Kondo M; Wada H; Nakamura M; Noda T; Damdinsuren B; Marubashi S; Miyamoto A; Takeda Y; Dono K; Umeshita K; Nakamori S; Wakasa K; Sakon M; Monden M
Oncol Rep; 2006 Aug; 16(2):249-55. PubMed ID: 16820899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
